share_log

中國中藥：聯合公告有關(1)要約人根據公司條例第673條通過計劃安排的方式將中國中藥控股有限公司私有化之附先決條件之建議及(2)建議撤銷中國中藥控股有限公司的上市地位之每月更新情況

TRAD CHI MED: JOINT ANNOUNCEMENTMONTHLY UPDATEIN RELATION TO(1) PRE-CONDITIONAL PROPOSAL TO PRIVATISECHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITEDBY THE OFFERORBY WAY OF A SCHEME OF ARRANGEMENTUNDER SECTION 673 OF THE COMPANIES ORDINANCEAND(2) PROPOSE

Hong Kong Stock Exchange ·  Jun 13 16:30
Summary by Futu AI
國藥集團共裕有限公司（「要約人」）正透過計劃安排方式，提出私有化中國中藥控股有限公司（「本公司」）的建議，並計劃撤銷本公司的上市地位。根據2024年2月21日及隨後的聯合公告，私有化建議的實施需滿足特定先決條件。要約人正在積極準備相關文件，並與有關當局進行溝通，以達成先決條件。這包括與適用的境外直接投資法律法規及中國反壟斷法相關的通知、備案或申請。本公司將按照收購守則，適時公布先決條件的滿足情況及計劃文件的寄發。股東及潛在投資者應注意，私有化建議尚未確定，並應謹慎行事。本聯合公告由董事會主席陳映龍先生代表要約人及本公司發出，日期為2024年6月13日。
國藥集團共裕有限公司（「要約人」）正透過計劃安排方式，提出私有化中國中藥控股有限公司（「本公司」）的建議，並計劃撤銷本公司的上市地位。根據2024年2月21日及隨後的聯合公告，私有化建議的實施需滿足特定先決條件。要約人正在積極準備相關文件，並與有關當局進行溝通，以達成先決條件。這包括與適用的境外直接投資法律法規及中國反壟斷法相關的通知、備案或申請。本公司將按照收購守則，適時公布先決條件的滿足情況及計劃文件的寄發。股東及潛在投資者應注意，私有化建議尚未確定，並應謹慎行事。本聯合公告由董事會主席陳映龍先生代表要約人及本公司發出，日期為2024年6月13日。
China National Pharmaceutical Group Co. has proposed the privatization of China Traditional Chinese Medicine Holdings Co., Ltd. (the "Company") through an arrangement plan and plans to delist the Company. According to the joint announcement on February 21, 2024 and thereafter, the implementation of the privatization proposal requires certain conditions to be fulfilled. The Offeror is actively preparing relevant documents and communicating with relevant authorities to meet the preconditions. This includes notifications, filings or applications related to applicable overseas direct investment laws and regulations and China's anti-monopoly law. The Company will timely disclose the fulfillment of preconditions and the mailing of the plan documents in accordance with the rules of acquisition. Shareholders and potential investors should note that the privatization proposal is not yet finalized and should act cautiously. This joint announcement is issued by Mr. Chen Yinglong, Chairman of the Board on behalf of the Offeror and the Company, and is dated June 13, 2024.
China National Pharmaceutical Group Co. has proposed the privatization of China Traditional Chinese Medicine Holdings Co., Ltd. (the "Company") through an arrangement plan and plans to delist the Company. According to the joint announcement on February 21, 2024 and thereafter, the implementation of the privatization proposal requires certain conditions to be fulfilled. The Offeror is actively preparing relevant documents and communicating with relevant authorities to meet the preconditions. This includes notifications, filings or applications related to applicable overseas direct investment laws and regulations and China's anti-monopoly law. The Company will timely disclose the fulfillment of preconditions and the mailing of the plan documents in accordance with the rules of acquisition. Shareholders and potential investors should note that the privatization proposal is not yet finalized and should act cautiously. This joint announcement is issued by Mr. Chen Yinglong, Chairman of the Board on behalf of the Offeror and the Company, and is dated June 13, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.